Queen's University Belfast seeks to appoint a clinical research organisation (CRO) to provide services in respect of conducting a multinational Phase II study in non-cystic fibrosis BE patients, sponsored by Novartis, across Europe. The trial will be jointly funded by Novartis and the EU Innovative Medicines Initiative (IMI) through the iABC consortium. IMI is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients (
http://www.imi.europa.eu/). Access to tender documentation is restricted to those companies who download, complete and submit a CDA to Queen's.